ReinerŽCatapanoADe BackerGGrahamITaskinenM-RWiklundO. ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J2011; 32(14): 1769–1818.
2.
GrahamIAtarDBorch-JohnsenKBoysenGBurellGCifkovaR. European guidelines on cardiovascular disease prevention in clinical practice: full text. Eur J Cardiovasc Prev Rehabil2007; 14(Supp 2): S1–S113.
3.
RydénLStandlEBartnikMVan den BergheGBetteridgeJde BoerMJ. Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary, The Task Force on Diabetes Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J2007; 28(1): 88–136.
4.
ManciaGDe BackerGDominiczakACifkovaRFagardRGermanoG. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J2007; 28(12): 1462–1536.
5.
BrunzellJDDavidsonMFurbergCDGoldbergRBHowardBVSteinJH. Lipoprotein management in patients with cardiometabolic risk: Consensus Conference Report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol2008; 51(15): 1512–1524.
6.
GenestJMcPhersonRFrohlichJAndersonTCampbellNCarpentierA. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult -- 2009 recommendations. Can J Cardiol2009; 25(10): 567–579.
7.
ContoisJHMcConnellJPSethiAACsakoGDevarajSHoefnerDM. AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices. Apolipoprotein B and cardiovascular disease risk: position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices. Clin Chem2009; 55(3): 407–419.
8.
ChapmanMJGinsbergHNAmarencoPAndreottiFBorenJCatapanoAL. for the European Atherosclerosis Society Consensus Panel. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for menagement. Eur Heart J2011; 32(11): 1345–1361.
9.
ReinerŽ. Combined therapy in the treatment of dyslipidemia. Fundam Clin Pharmacol2010; 24(1): 19–28.
